- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03937206
Evaluation of the Pharmacokinetics, Safety and Effects of NutriterraTM in Healthy Adults
A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study to Evaluate the Pharmacokinetics, Safety and Effects of NutriterraTM in Healthy Adult Subjects
The blood lipid profile plays a role in health and disease states and is affected by many genetic and lifestyle factors. On the more extreme side, hyperlipidemia (a condition characterized by hypertriglyceridemia, hypercholesteremia, or both) is a risk factor for coronary heart disease (CHD) 1. CHD is the most common form of cardiovascular disease (CVD); it is characterized by arterial obstructions or blockages, and is a leading cause of heart attacks and strokes 2. Specifically, blood lipids including triglycerides (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), and the ratio of TC: high density lipoprotein (HDL) cholesterol, are key modifiable risk factors for CHD. Hyperlipidemia is thought to be caused or promoted by sedentary lifestyle, obesity, or uncontrolled type 2 diabetes 2. Therefore, lifestyle factors, like the modification of dietary lipids to maintain a healthy blood lipid profile are warranted.
There are many beneficial effects of omega-3 fatty acids in terms of cardiovascular disease and the nervous system in general, as well as emerging research on DHA supplementation in acute brain and spinal cord injury. Demand for dietary omega-3's, either through increased fish consumption or through DHA supplementation, is expected to increase, particularly as the baby boomer population adds to the ranks of senior citizens concerned about and/or susceptible to health issues such as dementia and Alzheimer's Disease. Availability of EPA and DHA in circulation is an important parameter in understanding biologic properties of fatty acids.
The purpose of this study is to evaluate the pharmacokinetic characteristics of ascending doses of NutriterraTM, as measured by plasma levels of total EPA, DHA, DPA and ALA under fed conditions. In addition, after a two-week (minimum) washout period, subjects will take product for 16 weeks to evaluate effects on cardiovascular markers as a measure of efficacy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Guelph, Ontario, Canada, N1G 0B4
- Nutrasource
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults 18 years to 80 years (inclusive) at time of screening with suitable veins for cannulation or repeated venipuncture.
- BMI ≥ 18.5 to ≤ 34.9 kg/m2 at the time of Screening
Female participants of childbearing potential (i.e. not surgically sterilized or post-menopausal greater than one year) must have negative urine pregnancy test and must be using an effective birth control method, defined as:
- Continuous use of oral or long acting injected contraceptive for at least 2 months prior to study entry, or
- Use of an intra-uterine device or implantable contraceptive, or
- Use of double barrier methods of birth control, or
- Abstinence from heterosexual intercourse
- Willing to avoid alcohol consumption for 24 h prior to every clinic visit
- Willing to avoid moderate to intense exercise 24 h prior to every clinic visit
- Consume less than 200 mg omega-3 per day based on validated Questionnaire
- Agrees to stop taking any vitamins, minerals, or any fatty acid containing dietary/herbal supplements that could potentially interfere with the study endpoints and will be washed out for two weeks prior to study product administration and throughout the study.
- Willing to maintain a stable diet and level of activity throughout the trial.
- Willing to keep a daily journal describing impact of dosage and tolerability.
- Able to comply with all protocol activities.
- Willing and able to provide informed written consent.
Exclusion Criteria:
- Consumption of fish within two weeks prior to the first investigational product administration and for the duration of the study.
- Used canola oil, fish oil, other omega-3 fatty acids (EPA and/or DHA) containing supplements within one (1) month of baseline (Visit 2) or any time during the study, other than the product being evaluated in this study.
- Have a known sensitivity or allergy to canola or any other ingredients in the test products.
- Individuals taking prescription or non-prescription health products that may affect the study endpoint (e.g. corticosteroids, prescription anti-inflammatory drugs, blood lipid-lowering drugs (e.g. statins, fibrates, bile acid exchanger resin, phytosterols, niacin or its analogues, carnitine, etc.) in the previous 6 months.
- Individuals taking any supplements with phytosterols, polyglucosamines (Chitosan) or other lipid-binding ingredients in the previous 3 months.
- Unstable use (i.e. initiation or change in dose) of antihypertensive medications or thyroid hormone replacement medications within 3 months prior to visit 1.
- Use of any weight-loss programs or weight-loss medications (prescription or over-the counter) including, but not limited to, lipase inhibitors, within 6 months prior to visit 1 and throughout the study.
- Pregnancy or lactation, or participant unwilling to take appropriate contraceptives for the duration of the study.
- History of blood clotting disorders or use of coagulation-inhibiting drugs (e.g. warfarin).
- History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (i.e. Crohn's disease, short bowel, acute or chronic pancreatitis or pancreatic insufficiency).
- Presence of major diseases such as diabetes, endocrine, cardiovascular, renal, or liver disease.
- History of neurological disease (e.g. Parkinson's disease, stroke, traumatic brain injury, etc.).
- History of cancer (excluding non-melanoma skin cancer and basal cell carcinoma) in the past 5 years.
- Uncontrolled hypertension defined as a seated resting systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg.
- Active psychiatric disease (hospitalized within the past 12 months of Screening).
- Documented medical history of immune disorder (such as HIV/aids, hepatitis B or hepatitis C) or positive laboratory results within 28 days of dosing.
- History of a surgical procedure for the treatment of obesity (i.e., gastric bypass, gastric banding).
- Taking potent CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, erythromycin, clarithromycin, telithromycin and nefazodone) within two weeks prior to first investigational product administration and throughout the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose
Low Dose (300mg TG Omega-3) - 1 capsule containing 1000mg NutriterraTM per capsule + 3 capsules containing 1000mg corn oil per capsule
|
Nutriterra 1000mg
Other Names:
Corn Oil 1000mg
|
Experimental: Mid Dose
Mid Dose (600mg TG Omega-3) - 2 capsules containing 1000mg NutriterraTM per capsule + 2 capsules containing 1000mg corn oil per capsule
|
Nutriterra 1000mg
Other Names:
Corn Oil 1000mg
|
Experimental: High Dose
High Dose (1200mg TG Omega-3) - 4 capsules containing 1000mg NutriterraTM per capsule
|
Nutriterra 1000mg
Other Names:
|
Placebo Comparator: Placebo
Placebo (0mg TG Omega-3) - 4 capsules containing 1000mg corn oil per capsule
|
Corn Oil 1000mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EPA Area Under the Curve
Time Frame: 72 hours
|
To determine the pharmacokinetics over a 72-hour period of NutriterraTM at three doses under fed conditions in healthy subjects
|
72 hours
|
DHA Area Under the Curve
Time Frame: 72 hours
|
To determine the pharmacokinetics over a 72-hour period of NutriterraTM at three doses under fed conditions in healthy subjects
|
72 hours
|
Triglycerides
Time Frame: 16 weeks
|
To evaluate the dose response and effect of NutriterraTM on triglyceride (TG) levels in healthy subjects
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total Cholesterol
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on total cholesterol
|
16 weeks
|
HDL-C
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on HDL-C
|
16 weeks
|
LDL-C
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on LDL-C
|
16 weeks
|
LDL-C/HDL-C ratio
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on LDL-C/HDL-C ratio
|
16 weeks
|
non-HDL-C
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on non-HDL-C
|
16 weeks
|
Omega-3 fatty acid profile in whole blood
Time Frame: 4 weeks
|
To determine the effect of daily use of NutriterraTM on whole blood omega-3 fatty acid profile
|
4 weeks
|
Omega-3 fatty acid profile in red blood cells
Time Frame: 16 weeks
|
To determine the effect of daily use of NutriterraTM on red blood cell omega-3 fatty acid profile
|
16 weeks
|
C-reactive protein
Time Frame: 4 and 16 weeks
|
To determine the effect of daily use of NutriterraTM on high sensitivity C-reactive protein (hs-CRP)
|
4 and 16 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NUSERPD-160001-RPD01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet